Clinical Trial Center, Jeonbuk National University Hospital
Jeonju, South Korea
NCT Number: NCT06361277
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0202 and C2202 and co-administration of C2205 and JW0201 in healthy volunteers under fasting conditions
Looking for future studies?
Notify Me19 year–55 year
All sexes
Interventional
Phase 1
Jeonju, South Korea
Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
Other names: Reference Drug(C2205 and JW0201) or Test Drug(JW0202 and C2202)
Time frame: Day1 0h ~ Day3 48h
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Time frame: Day1 0h ~ Day3 48h
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
JW Pharmaceutical
Industry
A Randomized, Open-label, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics and Safety of JW0202 and C2202 or C2205 and JW0201 After Oral Administration in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details